FINDEX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 998 JPY | -0.40% |
|
-3.76% | -3.11% |
| 04-15 | Findex Disposes 10,855 Shares Worth 11 Million Yen as Restricted Stock Compensation | MT |
| 03-28 | Findex to Allot Treasury Shares Worth 12 Million Yen to Directors, Executive Officers | MT |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.11% | 160M | - | ||
| -3.97% | 29.89B | C | ||
| +46.60% | 9.73B | C- | ||
| +36.91% | 4.51B | B- | ||
| -31.88% | 2.58B | C- | ||
| -9.44% | 1.6B | - | C+ | |
| -27.08% | 1.26B | B | ||
| +7.60% | 962M | C | ||
| -43.47% | 960M | - | ||
| -43.97% | 781M | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 3649 Stock
- Ratings FINDEX Inc.
